Reported Q: Q4 2024 Rev YoY: -1.9% EPS YoY: +11.1% Move: -0.64%
Hormel Foods Corporation
HRL
$24.93 -0.64%
Exchange NYSE Sector Consumer Defensive Industry Packaged Foods
Q4 2024
Published: Dec 5, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for HRL

Reported

Report Date

Dec 5, 2024

Quarter Q4 2024

Revenue

3.14B

YoY: -1.9%

EPS

0.40

YoY: +11.1%

Market Move

-0.64%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $3.14B down 1.9% year-over-year
  • EPS of $0.40 increased by 11.1% from previous year
  • Gross margin of 16.6%
  • Net income of 220.20M
  • ""Transform and Modernize is on track, delivering value and helping to return the company to its historical earnings trajectory."" - Jim Snee
HRL
Company HRL

Executive Summary

Hormel Foods delivered a solid fourth quarter that capped a year of notable transformation and operating cash-flow leadership. Q4 revenue was $3.139 billion with a gross margin of 16.6% and an operating margin of 9.38%, resulting in GAAP net income of $220.2 million and GAAP EPS of $0.40 for the period. For the full year, Hormel reported net sales of $11.9 billion, gross margin of 17.0%, and operating margin of 9.0% (adjusted at 9.6%), underscoring a quality, value-added portfolio resilient to macro dynamics. Management attributed the year to strong execution across Retail, Foodservice and International segments and highlighted the Transform and Modernize (T&M) initiative as a core driver of earnings quality and cash-flow strength. The company announced $75 million of operating income benefits in year one of T&M, with projected annualized run-rate benefits of $100–$150 million in 2025, expanding the company’s growth flywheel as it reinvests in brands, capabilities and capacity.
Key 2024 outcomes include record operating cash flow of $1.3 billion and a post-dividend-culture milestone: a 59th consecutive increase to the annual dividend, now $1.16 per share for fiscal 2025. Hormel also divested Hormel Health Labs, streamlining the portfolio and focusing on core, higher-margin offerings. Looking ahead, Hormel framed 2025 guidance of net sales in a $11.9–$12.2 billion band, organic net sales growth of 1–3%, and adjusted EPS of $1.58–$1.72, incorporating anticipated near-term headwinds (e.g., Planters investment, whole-bird turkey dynamics) and profit leverage from the T&M program. The long-term growth algorithm remains 2–3% organic net sales growth and 5–7% operating income growth, supported by a broadened brand portfolio and ongoing portfolio optimization.
Overall investment thesis: HRL is positioned to translate T&M-driven efficiency into durable growth that should improve capital efficiency, maintain dividend leadership, and progressively de-risk commodity exposures through a more value-added mix and stronger category leadership.”

Key Performance Indicators

Revenue
Decreasing
3.14B
QoQ: 8.27% | YoY: -1.88%
Gross Profit
Increasing
521.23M
16.61% margin
QoQ: 6.73% | YoY: 1.32%
Operating Income
Increasing
294.48M
QoQ: 24.41% | YoY: 9.05%
Net Income
Increasing
220.20M
QoQ: 24.62% | YoY: 12.38%
EPS
Increasing
0.40
QoQ: 25.00% | YoY: 11.11%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2025 2,988.81 0.31 -0.3% View
Q4 2024 3,138.09 0.40 -1.9% View
Q3 2024 2,898.44 0.32 -9.4% View
Q2 2024 2,887.35 0.34 -2.6% View
Q1 2024 2,996.91 0.40 +0.7% View